


Pharmaceuticals & Biotechnology | Small Cap
Hester Biosciences Ltd shows a mixed financial performance. The company demonstrates strong growth and profitability, reflected in high scores for growth and profitability ratios. Its solvency is also good, indicating a stable financial structure. However, there are areas of concern, particularly in efficiency and liquidity. The company's efficiency ratios suggest challenges in asset utilization, while liquidity ratios indicate potential difficulties in meeting short-term obligations. The financial ratios also need improvement, reflecting lower earnings per share and higher capital expenditures. While the company shows robust growth and profitability, it needs to address its efficiency and liquidity to ensure long-term financial stability.
Hester Biosciences Ltd shows a mixed financial performance. The company demonstrates strong growth and profitability, reflected in high scores for growth and profitability ratios. Its solvency is also good, indicating a stable financial structure. However, there are areas of concern, particularly in efficiency and liquidity. The company's efficiency ratios suggest challenges in asset utilization, while liquidity ratios indicate potential difficulties in meeting short-term obligations. The financial ratios also need improvement, reflecting lower earnings per share and higher capital expenditures. While the company shows robust growth and profitability, it needs to address its efficiency and liquidity to ensure long-term financial stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
34.59
Industry Median
32.38
Small Cap Median
29.54
P/E RATIO
32.38
P/B RATIO
5.01
Industry Median
3.38
Small Cap Median
2.89
P/S RATIO
5.34
Industry Median
3.65
Small Cap Median
2.73
Others
PEG RATIO
0.00
EV/EBITDA RATIO
17.63
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2118 as on Jul 12, 2026.
The growth ratios reflect strong growth across key metrics. High revenue, operating profit, EPS, asset, and net income growth rates demonstrate the company's ability to expand its operations and increase profitability. Sustaining this growth trajectory will be crucial for long-term success and shareholder value creation. The company is performing well in terms of growth and is expected to perform well in future.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 9.81 | 13.19 | 14.66 | 1.97 | 7.07 |
| Operating Profit Growth Rate | -13.04 | -15 | 5.88 | 14.81 | 40.32 |
| Earnings Per Share (EPS) Growth | 14.21 | -32.28 | -29.04 | 45.48 | 102.45 |
| Asset Growth Rate | 36.74 | 19.22 | -1.19 | -1.36 | 3.83 |
| Net Income Growth Rate | 11.43 | -28.21 | -25 | 38.1 | 96.55 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 36.20 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 76.34 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 26.36 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.03 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 40.99 | Overvalued | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 17.51 | Undervalued | 77.00 | 0.81 | 76.00 |
| 9 | Sakar Healthcare Ltd | 6.89 | 60.18 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 32.38 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 13 | Medicamen Biotech Ltd | 5.73 | 34.51 | Neutral | 20.00 | 6.94 | 10.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 23.57 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 51.66 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Wanbury Ltd | 4.65 | 31.96 | Neutral | 88.00 | 18.93 | 43.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -277.51 | Neutral | 187.00 | -1.50 | -7.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤3rd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Annual Report⬤2nd Jul 26
Annual Report 2025-26
UNDEFINED SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT